Results 71 to 80 of about 5,427 (131)

The Differential Impact of Neoadjuvant Therapies on the Tumor Microenvironment, Peripheral Biomarkers, and Survival in Pancreatic Cancer: A Retrospective Cohort Study. [PDF]

Cancers (Basel)
Silva T, Yamazaki T, Creasy JM, Gerry JM, Zheng-Lin B, Srivastava AJ, Young KH.   +6 more
europepmc   +1 more source

Developments & Potential of Nanotechnology for the Detection and Treatment of Pancreatic Cancer. [PDF]

Int J Nanomedicine
O'Meara D, Hoskins C.
europepmc   +1 more source

Recent paclitaxel formulation strategies: expanding the therapeutic index by addressing biopharmaceutical and toxicity limitations. [PDF]

Arch Pharm Res
Lee J, Choi MK, Song IS.
europepmc   +1 more source

Precise Ratiometric Drug Delivery for the Treatment of Triple-Negative Breast Cancer. [PDF]

ACS Nano
Kang RH, Rasoulianboroujeni M, Kianpour M, Repp L, Ponik SM, Kwon GS.   +5 more
europepmc   +1 more source

Hypoxia-activated paclitaxel prodrugs enable PD-L1 degradation to potentiate cancer chemo-immunotherapy. [PDF]

J Nanobiotechnology
Zhou S, Zhang Q, Han H, Chen G, Wang P, Xue S, Pei Q, Xie Z, Meng X.   +8 more
europepmc   +1 more source

Integrated Computational Modeling Reveals a Structurally Plausible Transient Paclitaxel-NK2R Interaction. [PDF]

Bioengineering (Basel)
Duda-Seiman C, Tartau LM, Hoinoiu B, Pit D, Dumitrascu V, Tanase AD, Rusu E, Luca A, Popa EG, Hoinoiu T.   +9 more
europepmc   +1 more source

Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Phase II, Open-Label, Randomized Study. [PDF]

Clin Cancer Res
Pelletier M, Yang J, Joshi M, Grauel A, Abecunas C, Altzerinakou MA, Zhou Z, Zhu X, Clark K, Li L, Bai LY, Milella M, Mercade TM, Tai WMD, Bockorny B, Grell P, Sivakumar S, Wong MK, Chee CE, Aparicio T, Prager G, Bostel G, Schiessl B, Maacke H, Dranoff G, Shaw A, Fabre C, Mataraza J, Malek S, Cremasco V.   +29 more
europepmc   +1 more source

Therapeutic Redox Reprogramming in Breast Cancer: From Antioxidant Modulation to Precision Nanomedicine. [PDF]

Antioxidants (Basel)
Kummer N, Gayibova S, Aripov T, Gül D, Dolaz M, Acet BÖ, Köse LP, Odabaşı M, Stauber RH, Acet Ö.   +9 more
europepmc   +1 more source

Towards targeted drugs and next generation of nanomedicines. [PDF]

Beilstein J Nanotechnol
Salvati A, Giordani S, Parak WJ.
europepmc   +1 more source

Heterocyclic modified paclitaxel prodrug nanoassemblies for stimuli-responsive delivery <i>via</i> lysosomal escape. [PDF]

Acta Pharm Sin B
Han M, Xu H, Yuan J, Li W, Zhang H, Fang H, Kuang Z, Yu Y, Wang D, Zhao Z, Luo C, Sun B, Sun J.   +12 more
europepmc   +1 more source